/BRSYF
BRSYF Stock - BrainsWay Ltd.
Healthcare|Medical - DevicesOTC
$8.73+0.00%
+$0.00 (+0.00%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $9.60
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BRSYF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.64 – $8.82
TARGET (TP)$10.04
STOP LOSS$8.03
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.27
52W High$8.73
52W Low$3.26
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $41.02M | $31.79M | $27.18M | $29.66M | $22.06M |
| Gross Profit | $30.58M | $23.48M | $20.05M | $23.06M | $17.00M |
| Gross Margin | 74.6% | 73.9% | 73.8% | 77.7% | 77.1% |
| Operating Income | $1.39M | $-4,959,000 | $-12,683,000 | $-4,999,000 | $-4,829,000 |
| Net Income | $2.92M | $-4,197,000 | $-13,349,000 | $-6,462,000 | $-5,385,000 |
| Net Margin | 7.1% | -13.2% | -49.1% | -21.8% | -24.4% |
| EPS | $0.09 | $-0.13 | $-0.43 | $-0.21 | $-0.24 |
Company Overview
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BRSYFBeat Rate
56%
Last 16 quarters
Avg Surprise
+23.4%
EPS vs Estimate
Beats / Misses
9/4
3 met exactly
Latest EPS
$0.04
Q4 2025
EPS Surprise History
Q1 24
+100.0%
$0.00vs$0.00
Q2 24
+100.0%
$0.00vs$0.00
Q3 24
+100.0%
$0.02vs$0.01
Q4 24
+185.7%
$0.02vs$0.01
Q1 25
+100.0%
$0.04vs$0.02
Q2 25
-33.3%
$0.02vs$0.03
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | — | — | — | — |
Q4 2025 | Nov 11, 2025 | — | $0.04 | — | — |
Q3 2025 | Aug 13, 2025 | — | $0.05 | — | — |
Q2 2025 | May 13, 2025 | $0.03 | $0.02 | -33.3% | ✗ MISS |
Q1 2025 | Mar 11, 2025 | $0.02 | $0.04 | +100.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $0.01 | $0.02 | +185.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.01 | $0.02 | +100.0% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.00 | $0.00 | +100.0% | ✓ BEAT |
Q1 2024 | Mar 6, 2024 | $0.00 | $0.00 | +100.0% | ✓ BEAT |
Q4 2023 | Nov 15, 2023 | $-0.01 | $-0.01 | -75.1% | ✗ MISS |
Q3 2023 | Aug 9, 2023 | $-0.08 | $-0.05 | +37.5% | ✓ BEAT |
Q2 2023 | May 17, 2023 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q1 2023 | Mar 15, 2023 | $-0.12 | $-0.12 | 0.0% | = MET |
Q4 2022 | Nov 16, 2022 | $-0.06 | $-0.15 | -150.0% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.07 | $-0.07 | 0.0% | = MET |
Q2 2022 | May 11, 2022 | $-0.09 | $-0.06 | +33.3% | ✓ BEAT |
Q1 2022 | Mar 9, 2022 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q4 2021 | Nov 17, 2021 | $-0.06 | $-0.10 | -66.7% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.06 | $-0.06 | 0.0% | = MET |
Latest News
Loading news...
Frequently Asked Questions about BRSYF
What is BRSYF's current stock price?
BrainsWay Ltd. (BRSYF) is currently trading at $8.73 per share. The stock has moved +0.00% today.
What is the analyst price target for BRSYF?
No analyst price targets are currently available for this stock.
What sector is BrainsWay Ltd. in?
BrainsWay Ltd. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the OTC exchange.
What is BRSYF's market cap?
BrainsWay Ltd. has a market capitalization of $0.34 billion, making it a small-cap company.
Does BRSYF pay dividends?
No, BrainsWay Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCCOY
BICO Group AB (publ)
$0.60
Mkt Cap: $0.2B
CLLKF
BICO Group AB (publ)
$1.97
Mkt Cap: $0.1B
CYBQF
CYBERDYNE Inc.
$1.39
Mkt Cap: $0.2B
CYBQY
CYBERDYNE Inc.
$1.07
Mkt Cap: $0.2B
GNFTF
Genfit S.A.
$4.14
Mkt Cap: $0.2B
MFCSF
Medical Facilities Corporation
$11.16
Mkt Cap: $0.2B
MKLNF
M1 Kliniken AG
$11.73
Mkt Cap: $0.2B
PXMBF
Paxman AB (publ)
$3.50
Mkt Cap: $0.1B
RLLVF
Relevium Technologies Inc.
$0.01
Mkt Cap: $0.0B
SPHDF
Santhera Pharmaceuticals Holding AG
$13.35
Mkt Cap: $0.2B
Explore stocks similar to BRSYF for comparison